Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERCULES phase 3 study of SAR442168 in nonrelapsing secondary progressive multiple sclerosis
MOH_2020-10-19_009416Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing SAR442168 with Placebo (2 arms). Primary endpoint: Confirmed disability progression over 6 months. Started Aug 2020; status: recruiting.
02
Drugs
tolebrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on MOH_2020-10-19_009416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-19_009416.